Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity

P. Klivényi, Gabrielle Gardian, Noel Y. Calingasan, Lichuan Yang, Reid Von Borstel, Joel Saydoff, Susan E. Browne, M. Flint Beal

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Administration of triacetyluridine (TAU) is a means of delivering exogenous pyrimidines to the brain, which may help to compensate for bioenergetic defects. TAU has previously been shown to be neuroprotective in animal models of Huntington's and Alzheimer's diseases. We examined whether oral administration of TAU in the diet could exert significant neuroprotective effects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity model of Parkinson's disease. Administration of TAU significantly attenuated MPTP-induced depletion of striatal dopamine and loss of tyrosine-hydroxylase-positive neurons in the substantia nigra. These findings suggest that administration of TAU may be a novel approach for treating neurodegenerative diseases associated with impaired mitochondrial function.

Original languageEnglish
Pages (from-to)87-92
Number of pages6
JournalNeuroMolecular Medicine
Volume6
Issue number2-3
Publication statusPublished - Oct 2004

Fingerprint

Neuroprotective Agents
Oral Administration
Corpus Striatum
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Pyrimidines
Huntington Disease
Tyrosine 3-Monooxygenase
Substantia Nigra
Neurodegenerative Diseases
Energy Metabolism
Parkinson Disease
Dopamine
Alzheimer Disease
Animal Models
4-phenyl-1,2,3,6-tetrahydropyridine
2',3',5'-tri-O-acetyluridine
Diet
Neurons
Brain

Keywords

  • Dopamine
  • Mitochondria
  • MPTP
  • Parkinson's disease
  • Triacetyluridine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Genetics
  • Cell Biology

Cite this

Klivényi, P., Gardian, G., Calingasan, N. Y., Yang, L., Von Borstel, R., Saydoff, J., ... Beal, M. F. (2004). Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. NeuroMolecular Medicine, 6(2-3), 87-92.

Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. / Klivényi, P.; Gardian, Gabrielle; Calingasan, Noel Y.; Yang, Lichuan; Von Borstel, Reid; Saydoff, Joel; Browne, Susan E.; Beal, M. Flint.

In: NeuroMolecular Medicine, Vol. 6, No. 2-3, 10.2004, p. 87-92.

Research output: Contribution to journalArticle

Klivényi, P, Gardian, G, Calingasan, NY, Yang, L, Von Borstel, R, Saydoff, J, Browne, SE & Beal, MF 2004, 'Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity', NeuroMolecular Medicine, vol. 6, no. 2-3, pp. 87-92.
Klivényi P, Gardian G, Calingasan NY, Yang L, Von Borstel R, Saydoff J et al. Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. NeuroMolecular Medicine. 2004 Oct;6(2-3):87-92.
Klivényi, P. ; Gardian, Gabrielle ; Calingasan, Noel Y. ; Yang, Lichuan ; Von Borstel, Reid ; Saydoff, Joel ; Browne, Susan E. ; Beal, M. Flint. / Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. In: NeuroMolecular Medicine. 2004 ; Vol. 6, No. 2-3. pp. 87-92.
@article{e371eb6188e04fbda39706284478671e,
title = "Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity",
abstract = "Administration of triacetyluridine (TAU) is a means of delivering exogenous pyrimidines to the brain, which may help to compensate for bioenergetic defects. TAU has previously been shown to be neuroprotective in animal models of Huntington's and Alzheimer's diseases. We examined whether oral administration of TAU in the diet could exert significant neuroprotective effects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity model of Parkinson's disease. Administration of TAU significantly attenuated MPTP-induced depletion of striatal dopamine and loss of tyrosine-hydroxylase-positive neurons in the substantia nigra. These findings suggest that administration of TAU may be a novel approach for treating neurodegenerative diseases associated with impaired mitochondrial function.",
keywords = "Dopamine, Mitochondria, MPTP, Parkinson's disease, Triacetyluridine",
author = "P. Kliv{\'e}nyi and Gabrielle Gardian and Calingasan, {Noel Y.} and Lichuan Yang and {Von Borstel}, Reid and Joel Saydoff and Browne, {Susan E.} and Beal, {M. Flint}",
year = "2004",
month = "10",
language = "English",
volume = "6",
pages = "87--92",
journal = "NeuroMolecular Medicine",
issn = "1535-1084",
publisher = "Humana Press",
number = "2-3",

}

TY - JOUR

T1 - Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity

AU - Klivényi, P.

AU - Gardian, Gabrielle

AU - Calingasan, Noel Y.

AU - Yang, Lichuan

AU - Von Borstel, Reid

AU - Saydoff, Joel

AU - Browne, Susan E.

AU - Beal, M. Flint

PY - 2004/10

Y1 - 2004/10

N2 - Administration of triacetyluridine (TAU) is a means of delivering exogenous pyrimidines to the brain, which may help to compensate for bioenergetic defects. TAU has previously been shown to be neuroprotective in animal models of Huntington's and Alzheimer's diseases. We examined whether oral administration of TAU in the diet could exert significant neuroprotective effects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity model of Parkinson's disease. Administration of TAU significantly attenuated MPTP-induced depletion of striatal dopamine and loss of tyrosine-hydroxylase-positive neurons in the substantia nigra. These findings suggest that administration of TAU may be a novel approach for treating neurodegenerative diseases associated with impaired mitochondrial function.

AB - Administration of triacetyluridine (TAU) is a means of delivering exogenous pyrimidines to the brain, which may help to compensate for bioenergetic defects. TAU has previously been shown to be neuroprotective in animal models of Huntington's and Alzheimer's diseases. We examined whether oral administration of TAU in the diet could exert significant neuroprotective effects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity model of Parkinson's disease. Administration of TAU significantly attenuated MPTP-induced depletion of striatal dopamine and loss of tyrosine-hydroxylase-positive neurons in the substantia nigra. These findings suggest that administration of TAU may be a novel approach for treating neurodegenerative diseases associated with impaired mitochondrial function.

KW - Dopamine

KW - Mitochondria

KW - MPTP

KW - Parkinson's disease

KW - Triacetyluridine

UR - http://www.scopus.com/inward/record.url?scp=24644518083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24644518083&partnerID=8YFLogxK

M3 - Article

C2 - 15970626

AN - SCOPUS:24644518083

VL - 6

SP - 87

EP - 92

JO - NeuroMolecular Medicine

JF - NeuroMolecular Medicine

SN - 1535-1084

IS - 2-3

ER -